| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensi...
Baupost Group, led by Seth Klarman, made major changes to its investment portfolio in the third quarter. A look at the changes.
Blue-chip stocks hit record highs as investors rotate toward old-economy leaders; AMD surges, gold rallies, oil slides on OPEC ...
- Reuters Citing UBS Conference Call
Pete Buttigieg says Trump's ATC attack is a distraction from his "bad deal" on health insurance and failure on "...
Officers of Elevance Health, Inc. (the "Company") expect to speak with investors over the next week. During these meeti...
Health insurer stocks fell after the Senate ended the shutdown without extending ACA subsidies, delaying the decision to Decemb...
Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew more confident about risk as...
Mizuho analyst Ann Hynes maintains Elevance Health (NYSE:ELV) with a Outperform and lowers the price target from $420 to $400.